We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Glycated Hemoglobin Levels Associated with Fibromyalgia

By LabMedica International staff writers
Posted on 30 May 2019
Fibromyalgia (FM) is one of the most frequent generalized pain disorders with poorly understood neurobiological mechanisms. More...
In the general population, the estimated global prevalence of FM is 2.7% with a 3 to 1 female to male ratio.

Patients afflicted with FM have chronic widespread pain and protean somatic symptoms including fatigue, non-restorative sleep, gastrointestinal complaints and problems of cognition and mood. Due to lower pain thresholds, patients with FM also have a higher incidence of symptomatic musculoskeletal and spinal disorders, which in themselves contribute to the financial burden of managing this disorder.

Scientists from the University of Texas Medical Branch (Galveston, TX, USA) recruited 23 people with fibromyalgia whose doctors had referred them to a specialist clinic for the treatment of muscular or connective tissue pain. Since there is a known association between small fiber neuropathy and FM, many of these patients had undergone laboratory investigations in commercial CLIA (United States Clinical Laboratory Improvement Act) accredited laboratories. This comprised diagnostic panels for peripheral neuropathy, which included HbA1c values.

The HbA1c values from 23 patients with FM (eight Hispanic; 11 White; four African-American; 21 females, two males) were compared with the HbA1c means of two independent control populations. One was a non-diabetic population with normal glucose tolerance and the second population used for confirmation was extracted from the National Health and Nutrition Examination Survey dataset (NHANES non-diabetic).

When the investigators compared the HbA1c test results of the people with fibromyalgia with those of age-matched controls, they found that the former group had significantly higher levels of HbA1c than the latter, indicating a measure of insulin resistance. The regression estimates that HbA1c values in patients with FM mean 0.59 ± 0.1 units higher than Framingham Offspring Study (FOS NGT) and 0.39 units higher than the NHANES non-diabetic values.

A subgroup of patients meeting criteria for pre-diabetes or diabetes (patients with HbA1c values of 5.7% or greater) who had undergone treatment with metformin showed dramatic improvements of their widespread myofascial pain, as shown by their scores using a pre- and post-treatment numerical pain rating scale (NPRS) for evaluation. These findings suggest a pathogenetic relationship between FM and IR, which may lead to a radical paradigm shift in the management of this disorder.

Miguel A. Pappolla, MD, a neurologist and first author of the study, said, “We showed that most, if not all, patients with fibromyalgia can be identified by their HbA1c levels, which reflects average blood sugar levels over the past 2 to 3 months. People with prediabetes with slightly elevated HbA1c values carry a higher risk of developing central (brain) pain, a hallmark of fibromyalgia and other chronic pain disorders.”

The authors concluded that insulin resistance (IR) is being increasingly associated with a broad number of neurological disorders and FM may be one additional condition. Their data provides preliminary evidence suggesting that IR may be a pathological substratum in FM and sets the stage for future studies to confirm these initial observations. The study was published on May 6, 2019, in the journal PLOS ONE.

Related Links:
University of Texas Medical Branch


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.